季節性アレルギー性鼻炎(Seasonal Allergic Rhinitis)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Seasonal Allergic Rhinitis Overview 7
Therapeutics Development 8
Pipeline Products for Seasonal Allergic Rhinitis – Overview 8
Pipeline Products for Seasonal Allergic Rhinitis – Comparative Analysis 9
Seasonal Allergic Rhinitis – Therapeutics under Development by Companies 10
Seasonal Allergic Rhinitis – Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Seasonal Allergic Rhinitis – Products under Development by Companies 13
Seasonal Allergic Rhinitis – Companies Involved in Therapeutics Development 14
Adamis Pharmaceuticals Corporation 14
FAES Farma SA 15
Glenmark Pharmaceuticals Ltd. 16
Merck & Co., Inc. 17
Mitsubishi Tanabe Pharma Corporation 18
Novartis AG 19
Ono Pharmaceutical Co., Ltd. 20
Shionogi & Co., Ltd. 21
VentiRx Pharmaceuticals, Inc. 22
Seasonal Allergic Rhinitis – Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
(azelastine hydrochloride + mometasone furoate) – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
(GSP 301-1 NS + GSP 301-2 NS) – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
APC-3000 – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
bepotastine besylate – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
bilastine – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
desloratadine – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ONO-4053 – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
S-555739 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
VAK-694 – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
VTX-1463 – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Seasonal Allergic Rhinitis – Recent Pipeline Updates 45
Seasonal Allergic Rhinitis – Dormant Projects 48
Seasonal Allergic Rhinitis – Discontinued Products 50
Seasonal Allergic Rhinitis – Product Development Milestones 51
Featured News & Press Releases 51
Oct 11, 2013: FDA Approves Sanofi’s Nasacort Allergy 24HR for Over-the-Counter Use 51
May 01, 2012: Ista Reports Positive Phase II Trial Results Of BEPOSONE Nasal Spray 51
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54